Cleo Diagnostics logo

CLEO Diagnostics Takes Ovarian Cancer Test from Lab to Commercialisation Phase, Says OCRF

ASX-listed Cleo Diagnostics is currently working to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery.

A more accurate test for ovarian cancer is now being taken from the lab bench into clinical use by Australian company Cleo Diagnostics (ASX:COV), according to the Ovarian Cancer Research Foundation (OCRF).


An article from OCRF revealed that the first phase of commercialisation began on August 22, 2023, and focuses on the production of an improved, more accurate diagnostic test for ovarian cancer.

The surgical triage test was funded by the OCRF, developed at the Hudson Institute of Medical Research led by Professor Andrew Stephens and is being commercialised by Cleo Diagnostics.

“This new test will help ensure that an optimal management plan can be put in place early, which will streamline the referral process and provide the best care for patients,” said Cleo Diagnostics lead medical advisor and professor Tom Jobling.

Cleo’s commercialisation efforts aim to lead to better outcomes for patients and save time and resources for the healthcare system. The clinical application of the ovarian cancer test would commence in 2025 upon granting of appropriate regulatory approvals, the article said.

To read the full article, click here.

Click here to connect with Cleo Diagnostics (ASX:COV)) for an Investor Presentation

.

COV:AU
The Conversation (0)
CLEO Further Expands Ovarian Cancer Trial with Siles Health

CLEO Further Expands Ovarian Cancer Trial with Siles Health

Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles Health

Download the PDF here.

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Download the PDF here.

Invion Limited

Successful Completion of Placement to Accelerate Clinical Programs

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce that it has successfully completed a new share placement (Placement) to raise $2.0 million to advance research and development in Photosoft™ as a potential treatment for a range of cancers.

Keep reading...Show less
Recce Pharmaceuticals

Japan Patent Allowance for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce’s Anti-infectives, expiry 2041.

Keep reading...Show less
Completion of Indonesian Seaweed Joint Venture Transaction

Completion of Indonesian Seaweed Joint Venture Transaction

BPH Global (BP8:AU) has announced Completion of Indonesian Seaweed Joint Venture Transaction

Download the PDF here.

Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less

Latest Press Releases

Related News

×